Drug recall · August 18, 2021
Nystatin Oral Suspension recall
Why: Lack of CGMP: This recall is being carried out due to potential for carry over of Senna Syrup.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Nystatin Oral Suspension, USP 100,000 units per mL, Cherry/Peppermint Flavor, Rx ONLY, packaged in a) 16 fl oz (473 mL) NDC 0121-0868-16; b) 2 fl oz (60 mL) NDC 0121-0868-02; Manufactured by: Pharmaceutical Associates, Inc. Greenville, SC 29605
- Lots / codes
Lots: a) C98F, C990 Exp. 30SEP2022, C9C2 Exp. 31OCT2022; b) C9E1 Exp. 31OCT2022
- Quantity
- a) 1002 cases (12 bottles/case); b) 458 cases (24 bottles/case)
- Company
- PAI Holdings, LLC. dba Pharmaceutical Associates Inc, Greenville, SC
- Distribution
- Distributed Nationwide in the USA
- Initiated
- July 29, 2021 · Voluntary: Firm initiated
- Classified
- August 12, 2021
- Reported
- August 18, 2021
- Ended
- December 2, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Nystatin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.